1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Sherr CJ: Principles of tumor suppression.
Cell. 116:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
5
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Honda R, Tanaka H and Yasuda H:
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
FEBS Lett. 420:25–27. 1997. View Article : Google Scholar
|
7
|
Wu X, Bayle JH, Olson D and Levine AJ: The
p53-mdm-2 auto-regulatory feedback loop. Genes Dev. 7:1126–1132.
1993. View Article : Google Scholar : PubMed/NCBI
|
8
|
Lin MW, Wu CT, Shih JY, Chang YL and Yang
PC: Clinico-pathologic characteristics and prognostic significance
of EGFR and p53 mutations in surgically resected lung
adenocarcinomas ≤2 cm in maximal dimension. J Surg Oncol.
110:99–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Campling BG and El-Deiry WS: Clinical
implication of p53 mutation in lung cancer. Mol Biotechnol.
24:141–156. 2003. View Article : Google Scholar : PubMed/NCBI
|
10
|
Huang CL, Yokomise H and Miyatake A:
Clinical significance of the p53 pathway and associated gene
therapy in non-small cell lung cancers. Future Oncol. 3:83–93.
2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Mogi A and Kuwano H: TP53 mutations in
nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Kishimoto Y, Murakami Y, Shiraishi M,
Hayashi K and Sekiya T: Aberrations of the p53 tumor suppressor
gene in human non-small cell carcinomas of the lung. Cancer Res.
52:4799–4804. 1992.PubMed/NCBI
|
13
|
Tammemagi MC, McLaughlin JR and Bull SB:
Meta-analyses of p53 tumor suppressor gene alterations and
clinicopathological features in resected lung cancers. Cancer
Epidemiol Biomarkers Prev. 8:625–634. 1999.PubMed/NCBI
|
14
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Flaman JM, Frebourg T, Moreau V,
Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron
L and Benhattar J: A simple p53 functional assay for screening cell
lines, blood, and tumors. Proc Natl Acad Sci USA. 92:3963–3967.
1995. View Article : Google Scholar : PubMed/NCBI
|
17
|
Smardová J, Nemajerová A, Trbusek M,
Vagunda V and Kovarík J: Rare somatic p53 mutation identified in
breast cancer: A case report. Tumour Biol. 22:59–66. 2001.
View Article : Google Scholar
|
18
|
Ishioka C, Frebourg T, Yan YX, Vidal M,
Friend SH, Schmidt S and Iggo R: Screening patients for
heterozygous p53 mutations using a functional assay in yeast. Nat
Genet. 5:124–129. 1993. View Article : Google Scholar : PubMed/NCBI
|
19
|
Waridel F, Estreicher A, Bron L, Flaman
JM, Fontolliet C, Monnier P, Frebourg T and Iggo R: Field
cancerisation and polyclonal p53 mutation in the upper
aero-digestive tract. Oncogene. 14:163–169. 1997. View Article : Google Scholar : PubMed/NCBI
|
20
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: Lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Smardová J, Smarda J and Koptíková J:
Functional analysis of p53 tumor suppressor in yeast.
Differentiation. 73:261–277. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Toyooka S, Tsuda T and Gazdar AF: The TP53
gene, tobacco exposure, and lung cancer. Hum Mutat. 21:229–239.
2003. View Article : Google Scholar : PubMed/NCBI
|
23
|
Rodin SN and Rodin AS: Origins and
selection of p53 mutations in lung carcinogenesis. Semin Cancer
Biol. 15:103–112. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gibbons DL, Byers LA and Kurie JM:
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13.
2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Xu Y, Wang L, Zheng X, Liu G, Wang Y, Lai
X and Li J: Positive expression of p53, c-erbB2 and MRP proteins is
correlated with survival rates of NSCLC patients. Mol Clin Oncol.
1:487–492. 2013.
|
26
|
Steels E, Paesmans M, Berghmans T, Branle
F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and
Sculier JP: Role of p53 as a prognostic factor for survival in lung
cancer: A systematic review of the literature with a meta-analysis.
Eur Respir J. 18:705–719. 2001. View Article : Google Scholar : PubMed/NCBI
|
27
|
Nikliński J, Niklińska W, Laudanski J,
Chyczewska E and Chyczewski L: Prognostic molecular markers in
non-small cell lung cancer. Lung Cancer. 34(Suppl 2): S53–S58.
2001. View Article : Google Scholar
|